相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
Comparative effectiveness of different localization techniques for non-palpable breast cancer. A systematic review and network meta-analysis
Christos Athanasiou et al.
EJSO (2022)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial
Corrado Tinterri et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Intraoperative Ultrasound-Guided Excision of Non-Palpable and Palpable Breast Cancer: Systematic Review and Meta-Analysis
Maggie Banys-Paluchowski et al.
ULTRASCHALL IN DER MEDIZIN (2022)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
False Negativity of Targeted Axillary Dissection in Breast Cancer
George Kirkilesis et al.
BREAST CARE (2021)
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer et al.
LANCET ONCOLOGY (2021)
Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward
David Krug et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2021)
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials
Sonia L. Villegas et al.
EUROPEAN JOURNAL OF CANCER (2021)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
Nadia Harbeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
Malin Dahlgren et al.
JNCI CANCER SPECTRUM (2021)
DEGRO practical guideline for partial-breast irradiation
V. Strnad et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Extended Prophylactic Antibiotics for Mastectomy with Immediate Breast Reconstruction: A Meta-analysis
Yang Hai et al.
PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN (2020)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Analysis of clinical management of infected breast implants and of factors associated to successful breast pocket salvage in infections occurring after breast reconstruction
Simonetta Franchell et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial
Viviana Galimberti et al.
LANCET ONCOLOGY (2018)
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
Alison U. Barron et al.
JAMA SURGERY (2018)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Utility of the CPS plus EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Frederik Marme et al.
EUROPEAN JOURNAL OF CANCER (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
Joerg Heil et al.
BRITISH JOURNAL OF CANCER (2015)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
Elizabeth A. Mittendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Capsular Contractures: A Systematic Review
Antonino Araco et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2009)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: A meta-analysis of randomized controlled trials
GP Barnsley et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer
U Veronesi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation
B Fisher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)